A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
Maha Hussain, Dana Rathkopf, Glenn Liu, Andrew Armstrong, Wm Kevin Kelly, Anna Ferrari, John Hainsworth, Adarsh Joshi, Rebecca R. Hozak, Ling Yang, Jonathan D. Schwartz, Celestia S. Higano
Research output: Contribution to journal › Article › peer-review
27Scopus
citations
Fingerprint
Dive into the research topics of 'A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer'. Together they form a unique fingerprint.